Printer Friendly

MilliporeSigma Collaborates with Baylor College of Medicine to Develop COVID-19 Vaccine Candidates.

M2 PHARMA-May 27, 2020-MilliporeSigma Collaborates with Baylor College of Medicine to Develop COVID-19 Vaccine Candidates

(C)2020 M2 COMMUNICATIONS

MilliporeSigma and Baylor College of Medicine have extended their collaboration to focus on process development and improvements to advance vaccine manufacturing to fight COVID-19, the company said.

MilliporeSigma, along with researchers at Baylor College of Medicine and the Texas Children's Hospital Center for Vaccine Development, is optimising the production process to advance two Covid-19 vaccine candidates.

MilliporeSigma will help to accelerate their suitability for large-scale manufacturing. This collaboration will focus on improvements to production efficiency, yield, robustness, scalability and costs.

The MilliporeSigma-Baylor teams will improve the manufacturing platform for the CoV RBD219-N1 vaccine candidate, which was originally developed to target SARS in 2011-2016.

Additionally, they will develop a new manufacturing platform for a second Covid-19 vaccine candidate to shorten the time to enter into Phase 1 clinical trials.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2020 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2020 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:May 27, 2020
Words:158
Previous Article:MiraDx Offers COVID-19 PCR Testing for California Skilled Nursing Facilities.
Next Article:Quest Diagnostics Introduces COVID-19 Diagnostic and Antibody Testing for Workplaces.
Topics:

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters